The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On April 17, Eli Lilly is set to expand its weight loss market share with a new product launch, reinforcing its leadership in the obesity drug sector. On April 21, UnitedHealth flagged challenges in a Medicare pilot program to cover obesity drugs, with uncertainty over whether health insurers would join the program. On the same day, Amazon announced it would offer a program for GLP-1 weight-loss drugs, allowing Amazon One Medical members to access Novo Nordisk's Wegovy and Eli Lilly's Foundayo. On April 22, Eli Lilly acquired Kelonia Therapeutics as part of its expansion into cancer treatments.